ReviewClinical rheumatology2014
Clinical features and prognostic factors of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a literature review of 105 cases from 1999 to 2011.
Review in Clinical rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 55 citations in OpenAlex.
- Characteristics of patients with initial diagnosis of systemic lupus erythematosus in emergency department and their outcomes: a retrospective single-center study.Clinical rheumatology · 2024Article
- Sulperazon-induced acute reactive thrombocytopenia during treatment of systemic lupus erythematosus: a case report.European journal of hospital pharmacy : science and practice · 2023Article
- Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review.Clinical rheumatology · 2022Review
- Coexistence of thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an Asian woman: a case report.The Journal of international medical research · 2022Article
- Application of PLASMIC Score in Risk Prediction of Thrombotic Thrombocytopenic Purpura: Real-World Experience From a Tertiary Medical Center in Taiwan.Frontiers in medicine · 2022Article
- Quiescent Systemic Lupus Erythematosus Manifesting with Thrombotic Thrombocytopenic Purpura and Acute Renal Failure: A Case Report and Short Literature Review.Mediterranean journal of rheumatology · 2021Article
- Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.Blood advances · 2021Article
- Case Report: Systemic lupus erythematous associated with thrombotic thrombocytopenic purpura, a diagnostic challenge.F1000Research · 2021Article
- Systemic lupus erythematosus presenting as thrombotic thrombocytopaenic purpura in a child: a diagnostic challenge.BMJ case reports · 2020Article
- Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study.Orphanet journal of rare diseases · 2020Article
- Advances in paediatrics in 2019: current practices and challenges in allergy, endocrinology, gastroenterology, public health, neonatology, nutrition, nephrology, neurology, respiratory diseases and rheumatic diseases.Italian journal of pediatrics · 2020Review
- An Autopsy Case of Mixed Connective Tissue Disease Complicated by Thrombotic Thrombocytopenic Purpura.Internal medicine (Tokyo, Japan) · 2020Article
- Connective Tissue Disorders in Patients With Thrombotic Thrombocytopenic Purpura: A Retrospective Analysis Using a National Database.Journal of clinical medicine research · 2019Article
- Clinical features and prognosis of patients with thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a review of 25 cases.Italian journal of pediatrics · 2019Article
- Systemic Lupus Erythematosus (SLE) with Acute Nephritis, Antineutrophil Cytoplasmic Antibody- (ANCA-) Associated Vasculitis, and Thrombotic Thrombocytopenic Purpura (TTP): A Rare Case Report with Literature Review.Case reports in rheumatology · 2019Article
- Pure lupus podocytopathy first presenting as thrombotic thrombocytopenic purpura-like syndrome.Clinical rheumatology · 2016Review
- Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura.Medicine · 2015Observational
- Clinicopathological and outcome analysis of adult lupus nephritis patients in China.International urology and nephrology · 2015Article
- Thrombotic thrombocytopenic purpura as an initial presentation of systemic lupus erythematosus with acquired ADAMTS 13 antibody.BMJ case reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to review clinical features, treatments, and prognostic factors of thrombotic thrombocytopenic purpura (TTP) associated with systemic lupus erythematosus patients (sTTP). The case reports of sTTP published in world literature from 1999 to 2011 were collected, and 105 cases were divided into death group and survival group. The epidemiologic characteristics, clinical manifestations, laboratory examinations, treatments, and prognostic factors were analyzed. We found that coexistence of renal and neurological impairments were significantly frequent in the death group (100%) than in the survival group (56.5%) (P = 0.002). Type IV was predominant in 57.7% of renal pathological damage, followed by type V (11.5%), type II (5.8%), and thrombotic microangiopathy (TMA) (5.8%). TMA appeared more frequently (50%) in the death group than in the survival group (6.25%) (P = 0.042). End-stage renal disease occurred in nine cases with type IV in five (55.6%), type TMA in one (11.1%), and unspecified in three cases (33.3%). Of 32 cases, 40.6% showed severe ADAMTS13 deficiency and returned to normal or mildly deficient after remission. The total mortality rate of sTTP was 12.4 % and the mortality rate of patients with infection (27.3%) was significantly higher than those without infection (8.4%) (P = 0.028). Plasma exchange and glucocorticoids were administrated in over 80% of cases with 65.7% remission rate, while additional cytotoxics or rituximab was mostly used in refractory sTTP and achieved over 90 % of remission rate. Above all, coexistence of renal and neurological impairments, infection, and renal damage with type IV or TMA might denote a poor prognosis of sTTP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.